Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms
Sankalp Arora, Jayastu Senapati, Indraneel Deshmukh, Prithviraj Bose, Lucia Masarova, Sanam Loghavi, Xuemei Wang, Graciela Nogueras-Gonzalez, Guillermo Montalban-Bravo, Gautam Borthakur, Courtney D DiNardo, Tapan Kadia, Lingsha Zhou, Dyana Saenz, Habiba Halim, Yesid Alvarado, Maro Ohanian, Koichi Takahashi, Nicholas J Short, Elias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero, Naveen Pemmaraju, Naval G Daver · 2026
Read Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms by Sankalp Arora, Jayastu Senapati, Indraneel Deshmukh, Prithviraj Bose, Lucia Masarova, Sanam Loghavi, Xuemei Wang, Graciela Nogueras-Gonzalez, Guillermo Montalban-Bravo, Gautam Borthakur, Courtney D DiNardo, Tapan Kadia, Lingsha Zhou, Dyana Saenz, Habiba Halim, Yesid Alvarado, Maro Ohanian, Koichi Takahashi, Nicholas J Short, Elias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero, Naveen Pemmaraju, Naval G Daver (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13520238.txt.
Description
Sankalp Arora and a large team report final results in 2026 of a phase 2 trial pairing ruxolitinib with azacitidine in MDS/MPN overlap syndromes. These blood disorders mix two disease families with poor outlooks. Fifty-two patients, median age 68, received ruxolitinib in 28-day cycles, with azacitidine added from the fourth cycle.
Responses occurred in 30 patients, or 58 percent, lasting a median of 13.6 months. After a median follow-up of 88.5 months, a quarter of patients remained alive, with median survival of 26.7 months and five-year survival of 33 percent. Patients reaching stem cell transplant did best. Low blood counts and pneumonia were the commonest severe side effects, and only three patients stopped treatment for toxicity.
Catalog record
| CREATOR | Sankalp Arora, Jayastu Senapati, Indraneel Deshmukh, Prithviraj Bose, Lucia Masarova, Sanam Loghavi, Xuemei Wang, Graciela Nogueras-Gonzalez, Guillermo Montalban-Bravo, Gautam Borthakur, Courtney D DiNardo, Tapan Kadia, Lingsha Zhou, Dyana Saenz, Habiba Halim, Yesid Alvarado, Maro Ohanian, Koichi Takahashi, Nicholas J Short, Elias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero, Naveen Pemmaraju, Naval G Daver |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59550 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |